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0022-2836/$ - see front matter © 2008 EEmrE is a Small Multidrug Resistance transporter (SMR) family member
that mediates counter transport of protons and hydrophobic cationic drugs
such as tetraphenylphosphonium (TPP+), ethidium, propidium and
dequalinium. It is thought that the selectivity of the drug binding site in
EmrE is defined by two negatively charged glutamate residues within a
hydrophobic pocket formed from six of the α-helices, three from each
monomer of the asymmetric EmrE homodimer. It is not apparent how such
a binding pocket accommodates drugs of various sizes and shapes or
whether the conformational changes that occur upon drug binding are
identical for drugs of diverse chemical nature. Here, using electron
cryomicroscopy of EmrE two-dimensional crystals we have determined
projection structures of EmrE bound to three structurally different planar
drugs, ethidium, propidium and dequalinium. Using image analysis and
rigorous comparisons between these density maps and the density maps of
the ligand-free and TPP+-bound forms of EmrE, we identify regions within
the transporter that adapt differentially depending on the type of ligand
bound. We show that all three planar drugs bind at the same pocket within
the protein as TPP+. Furthermore, our analysis indicates that, while
retaining the overall fold of the protein, binding of the planar drugs is
accompanied by small rearrangements of the transmembrane domains that
are different to those that occur when TPP+ binds. The regions in the EmrE
dimer that are remodelled surround the drug binding site and include
transmembrane domains from both monomers.© 2008 Elsevier Ltd. All rights reserved.Edited by J. Bowie Keywords:multidrug resistance; membrane protein; structure; conformationIntroduction
EmrE is an Escherichia coli Small Multidrug
Resistance (SMR) protein that couples inward
translocation of two protons with the counter-
transport of a broad range of hydrophobic cations,
such as tetraphenylphosphonium (TPP+), ethidium
and methyl viologen.1,2 EmrE contains 110 amino
acids that form four transmembrane (TM) α-
helices.3,4 A low resolution (7.5 Å) projection
structure3 and 3D structure of EmrE in complex
with its substrate TPP+ have been determined by
electron cryomicroscopy (cryo-EM) of two-dimen-ess:
lsevier Ltd. All rights reservesional (2-D) crystals.5 The structure revealed that
EmrE is composed of eight helices arranged as an
asymmetric dimer within the membrane. The
dimeric arrangement of EmrE was corroborated by
analytical ultracentrifugation and substrate binding
studies.6,7 EmrE has been proposed to adopt a dual
topology configuration in the bacterial membrane,
based on the low-resolution structural information,5
GFP/PhoA fusion-based topology mapping and
mutagenesis,8 although this has been disputed
based mainly on cross linking data.9 The low-
resolution cryo-EM structure revealed the position
of TPP+ in the middle of an eight-helix transmem-
brane bundle.5 Based upon cryo-EM data and
evolutionary constraints, a model for EmrE has
been built;10 the model is supported by extensive
mutagenesis studies that identified residues likely to
be involved in substrate binding.1,11,12d.
1095Cryo-EM Determination of EmrE StructuresTo achieve multi-specific drug binding and trans-
port EmrE has evolved a hydrophobic pocket with a
pair of negatively charged glutamic acid residues
(Glu14), which are crucial for direct transporter–
ligand interactions, substrate translocation and
coupling to the transmembrane proton gradient.13
By analogy with the soluble multidrug binding
proteins QacR14 and BmrR,15 the binding site of
EmrE could be assumed not to require a perfect
stereochemical fit with the drugs, which is believedto be a common principle in all multidrug binding
proteins.13 Binding of hydrophobic cations to EmrE
is therefore thought to be via non-specific hydro-
phobic interactions and the ionic forces between the
two E14 residues and the delocalized positive
charge of the drug. Such a ‘simple’ binding pocket
would reduce the evolutionary constraints on the
protein and ensure broad substrate specificity.
However, it is not clear how the binding of EmrE
can accommodate drugs of different sizes andFig. 1. Substrates used for EmrE
2-D crystallization. (a) Chemical
structures of the three substrates:
ethidium (Eth+), propidium (PP2+)
and dequalinium (DQ2+); tetraphe-
nylphoshonium (TPP+) is shown for
comparison. (b) Competition curves
confirm that the chosen substrates
have micromolar or submicromolar
affinities for EmrE. The data shown
are from a single representative
[3H]TPP+ displacement experiment,
performed on detergent-solubilized
EmrE containing a final [3H]TPP+
concentration of 6 nM. IC50 values
were used to estimate the Ki of the
competitors using Cheng–Prusoff
equation,23 with a Kd of TPP
+
binding of 2.4 nM: IC50 values
were 1.8 μM, 33 nM and 147 nM
for Eth+, PP2+ and DQ2+ respec-
tively, corresponding to Ki values of
1.0±0.9 μM, 19±4 nMand 83±9 nM.
(c) Exchange of [3H]TPP+ bound to
2-D crystals for unlabeled sub-
strates. Residual [3H]TPP+ bound
to EmrEwasmeasured (n=3) after a
1000-fold dilution and 5 h incuba-
tion with and without propidium
and dequalinium; error bars repre-
sent the SEM.
1096 Cryo-EM Determination of EmrE Structuresshapes, and whether different conformational
changes are required.
We have, therefore, used cryo-EM of 2-D crystals
to determine the projection structures of EmrE
bound to three different substrates to address thisquestion. Comparison of these projections with
those obtained previously, with and without TPP+
bound, shows that the multidrug binding site of
EmrE is flexible and adopts distinct conformations
dependent on the nature of the substrate.Fig. 2. The projection maps of
planar drug-bound EmrE. (a–c) The
2-D crystals of EmrE bound to an
indicated drug were subjected to
cryo-EM and image analysis, as
described under “Materials and
Methods” (Eth+,ethidium; PP2+,
propidium; DQ2+, dequalinium).
The projection maps were plotted
using NPO, with contours ranging
from −500 to 500, with a step of 25;
the 0 contour is omitted. The
crystallographic asymmetric unit
consists of a tetramer composed of
two asymmetric dimers related by
an in-plane 2-fold axis. One tetra-
mer is coloured red and the other
blue.
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Crystallization of EmrE with various substrates
EmrE was previously crystallized by dialysis in the
presence of lipids to form 2-D crystals either with or
without bound TPP+, a high-affinity substrate3,5,16
that binds to EmrE with an affinity of 2 nM7. All the
previously obtained projection maps and the low-
resolution 3D structure of EmrE were determined
using these 2-D crystals. To gain insights into the
mechanisms underlying the substrate promiscuity of
EmrE, it was critical to gather structural data on its
complexes with other drugs. Therefore, three differ-
ent substrates were chosen to investigate properties
of the EmrE drug binding pocket. Ethidium (Eth+),
propidium (PP2+) and dequalinium (DQ2+) all differ
structurally from TPP+ by being predominantly
planar molecules rather than tetrahedral (Fig. 1a).23
Eth+ contains a planar triple aromatic ring system
and, although PP2+ is very similar to Eth+, it contains
a second tertiary amine and therefore carries a 2+
charge. Finally, DQ2+ has two planar cationic ‘head
groups’ separated by an aliphatic C10 linker.
Radioligand competition binding assays showed
that each of the ligands possesses micro- or sub-
micromolar affinity for EmrE, with Ki values for Eth
+,
PP2+ and DQ2+ of 1.0 μM, 19 nM and 83 nM,
respectively (Fig. 1b). Crystallisation trials were
therefore performed in the presence of either excess
Eth+, PP2+ or DQ2+ to obtain 2-D crystals of the
various EmrE–substrate complexes. Crystals of the
Eth+-bound form of EmrEwere of reasonable quality,
although they were not as good as TPP+–EmrE
crystals. However, the inclusion of either PP2+ or
DQ2+ during 2-D crystallizations resulted in either
extremely poorly ordered crystals or large unordered
vesicles, both unsuitable for structure determination.
We speculated that the reason for this disorder wasTable 1. Electron crystallographic data
Crystal form EmrE-ethidium
Plane group symmetry p2
Unit cell dimensions
a (Å) 74.57±0.57
b (Å) 89.93±1.48
γ (deg.) 106.69±1.16
No. images 12
Range of defocus (Å) 4113_10488
No. unique reflections 191
Total observations 1694
Overall phase residual 27.70
Temperature factor Bxy (Å) 347
Resolution range (Å)
No. of unique
reflections
Phase
residuals
∞–15.81 40 12.99
15.81–11.18 39 21.36
11.18–9.13 38 22.15
9.13–7.90 38 30.66
7.90–7.07 34 56.40
7.07–6.45 33 74.63
6.45–5.98 26 89.67due to the amphipathic nature of PP2+ and DQ2+,
which resulted in them partitioning into the lipid
bilayer and disrupting the molecular interactions
necessary for 2-D crystal formation. We therefore had
to use substrate exchange to substitute the TPP+ in
2-D crystals of the TPP+–EmrE complex for either
PP2+ or DQ2+. Ligand exchangewas accomplished by
dialyzing 2-D crystals of TPP+-bound EmrE against a
1000-fold excess of buffer containing either PP2+ or
DQ2+ for 5 h. The extent of the ligand exchange was
estimated by using [3H]TPP bound to EmrE 2-D
crystals during the exchange reaction. Only 1–3% of
radioactive TPP+ remained bound to the 2-D crystals
of EmrE after a 5 h incubation following a 1000-fold
dilution of the 2-D crystals when the dialysis buffer
contained either PP2+ or DQ2+ (Fig. 1c), suggesting
that the structural data would be dominated (N97%)
by contributions from EmrE bound to the exchanged
ligand. Under the conditions used for the ligand
exchange, equilibriumwas nearly reached, but longer
incubations could have resulted in a further deteriora-
tion of crystallinity, so exchange reactions were
limited to 5 h.
Projection structures of ethidium-,
propidium- and dequalinium-bound EmrE
The crystals obtained in the presence of Eth+ were
smaller than the TPP+-bound crystal form, but
reasonably well ordered, judged by optical diffrac-
tion of the cryo-EM micrographs and further image
processing. The projection structurewas obtained by
merging data from the 12 best images. The resolution
of the projection structure extended to 7 Å, compar-
able to that of the previously determined EmrE
projections with and without TPP+ (Fig. 2a, Table 1).
The crystals that underwent ligand exchange (PP2+-
and DQ2+-bound crystal forms) were morphologi-
cally indistinguishable from the parental TPP+-bound
EmrE 2-D crystals. However, image processingEmrE-propidium EmrE-dequalinium
p2 p2
69.33±0.51 70.05±0.45
83.38±0.46 83.92±1.26
106.05±0.54 105.75±0.45
7 5
6202_16069 5614_15612
126 102
805 615
40.99 27.79
288 344
No. of unique
reflections
Phase
residuals
No. of unique
reflections
Phase
residuals
32 25.30 31 11.06
25 37.72 26 22.36
29 24.77 26 24.10
16 63.29 11 68.20
22 73.17 7 72.83
11 64.41 4 52.72
16 71.99 7 96.03
Fig. 3. Averaged projection maps of EmrE with bound
TPP+ and three different planar drugs. (a–d) Maps of the
density corresponding to the EmrE tetramer bound to
indicated drugs, after image interpolation and averaging
of the two halves of the non-crystallographic tetramer. The
red coloured contours in the right half of each map show
the differences between the two dimers within a tetramer
(the difference maps were obtained by subtraction of the
mirror images, as described in “Materials and Methods”).
The coordinate grid imposed on the projection maps
(x-axis: a–d; y-axis: 1–5) is arbitrary, although the x=0 line
coincides with the in-plane non-crystallographic 2-fold
axis used in the averaging procedure.
1098 Cryo-EM Determination of EmrE Structuresrevealed that the substrate exchange procedure led to
distortions within the crystals and, subsequently, to
loss of their quality. Most of the imaged EmrE 2-D
crystals suffered fragmentation and were rendered
unsuitable for structural work. We hypothesise that
the disruption of the crystal lattice was largely due to
partitioning of the PP2+ or DQ2+ into the lipid bilayer
and disrupting EmrE crystal contacts, although we
cannot fully discount contributions from an addi-
tional conformational change accompanying the
binding of PP2+ or DQ2+. Only a small proportion
of crystalline areas within a few of the observed 2-D
crystals remained sufficiently ordered for further
processing. To obtain the projection structures for
PP2+- and DQ2+-bound forms of EmrE, 7 and 5
images were merged, respectively (Fig. 2b and c,
Table 1). Despite the strong effects of ligand exchange
on the crystallinity of the specimen, the PP2+–EmrE
and DQ2+–EmrE projection maps contained reliable
information at 8–9 Å (Table 1): the effective resolution
thresholds for both projection maps were 8.2 Å. All
three projection structures obtained from Eth+-, PP2+-
and DQ2+-bound EmrE crystals had p2 symmetry,
identical to the TPP+-bound crystals.
Averaged projection structures of EmrE bound
to mono- and bivalent planar substrates
At the resolution of the projection maps obtained,
all secondary structure features seen in the higher
resolution projections of EmrE were clearly resolved
(Fig. 2). The repetitive unit in the crystals was the
crystallographic tetramer (coloured either blue or
red in each of the maps in Fig. 2), but previous work
shows that the minimal functional unit for substrate
binding is the dimer.7 Careful inspection clearly
revealed small differences between the two halves of
the tetramer related by two fold non-crystallo-
graphic symmetry of EmrE in each of the projection
maps. These discrepancies between the dimers were
more pronounced in the density maps obtained with
PP2+ and DQ2+, where only a limited amount of data
was available. To improve further the resolution of
the asymmetric dimer, the two dimers in the
crystallographic tetramer were averaged using the
MRC software for electron micrograph analysis,17 as
described in “Materials andMethods”. The resulting
averagedmaps calculated from the data andmerged
to 7 Å are shown in Fig. 3. Evident from the red con-
tours in Fig. 3, the asymmetry within the crystal-
lographic tetramer was highest in the PP2+-bound
EmrE projection map, although the data extended to
about the same resolution as that for the DQ2+-bound
form (Table 2, “RMS mirr.”).
The three projection structures of EmrE were
superficially similar to each other and to those
obtained previously (Fig. 3). In order to quantita-
tively assess the similarity between all ligand-bound
(TPP+ and planar drugs) and ligand-free (apo-)
EmrE projection maps, we also calculated the
averaged dimer TPP+–EmrE map from the p2-
symmetrised projection structure16 (as described
under “Materials and Methods”; Fig. 4b, Table 2).The apo form (Fig. 4a) did not require averaging,
because the projection maps from which it was
derived were in space group c222 that contains a
crystallographic in-plane 2-fold relating the two
asymmetric dimers in the tetramer.16 Thus, interpola-
tion and averaging served two purposes, improving
the signal/noise level in the resulting projection
structures and, more importantly, allowing the direct
Table 2. Statistics for map averaging and comparisons
For definitions of the abbreviations and the calculation of the numbers, see Materials and Methods.
1099Cryo-EM Determination of EmrE Structurescomparisons of the projection maps calculated
from 2-D crystals with either p2 (TPP+, Eth+, PP2+
and DQ2+) or c222 symmetry (apo-EmrE).
The resolution at which the comparisons of all
maps could be performed was limited by the
resolution of the DQ2+-bound EmrE map (effective
resolution threshold of 8.2 Å). To choose an optimal
resolution, we merged and averaged all five maps at
7, 8, 9 and 10 Å. We then determined the “RMS
difference” (the RMS deviation of the total density
from the average density in the map; Table 2) for
difference maps between each projection map and
the TPP+–EmrE. We found that the RMS deviations,
and therefore the experimental error, were lowest at
9 Å for all planar ligand-bound EmrE projection
maps. Therefore, all maps were compared and
cross-correlated at 9 Å resolution. The maps of
TPP+–EmrE, Eth+–EmrE and apo-EmrE contained
structural information below that threshold, and
were compared separately at 7 Å resolution.
Detailed comparisons between projection maps
Comparisons were made between all the projec-
tion maps and plotted at either 9 Å resolution (Fig. 4)
or, where the data allowed, at 7 Å resolution (Fig. 5).
Table 3 provides the cross-correlation coefficients for
all the comparisons. From these data it is clear that
there are three distinct projection structures, namely
apo-EmrE, TPP+-bound EmrE and planar drug-
bound EmrE. The differences between apo-EmrE
and TPP+–EmrE have been previously described16
and are reproduced in Fig. 4b, with the large negativedensity peak at the B2/C2 boundary representing
bound TPP+. Figure 4c–e show similar negative
peaks, which are likely to represent either Eth+, PP2+
or DQ2+ in each case. In addition, there are density
differences in each of the different density maps for
Eth+, PP2+ and DQ2+ in the C1 area, suggestive of a
movement of this helix, as seen upon TPP+ binding,
although there appears to be an increase in the
magnitude of the movement when planar drugs are
bound, compared to TPP+ (Fig. 4f–h).
Additional changes are seen in the areas A3, D3
and D4 of the 7 Å resolution map ‘Eth+ minus TPP+’
(Fig. 5c). These changes are associated with the
helices that form the substrate binding pocket,
whereas there appear to be fewer and smaller
density changes associated with the pair of helices
in squares B&C, 4&5. These two helices may
represent helix 4, one from each monomer, and are
notable in that they are about 9 Å apart centre to
centre along their whole length and so probably
represent a strong and stable association; in addi-
tion, being separated from the ligand binding
pocket, it is unlikely they are contributing to any
conformational change during ligand binding.Discussion
Versatile recognition of diverse chemical structures
is a feature of the multidrug binding proteins and
transporters. Most of what we know about the
structural basis of multi-specific drug recognition
comes from the structural studies on the soluble
Fig. 4. Comparison between the averaged projection structures of ligand-free and planar drug-bound EmrE. (a)
Density map of the apo form of EmrE, truncated to 9 Å resolution, calculated from the apo-EmrE projection obtained by
imaging 2-D crystals of space group c222.3 (b) Projection map of TPP+–EmrE, truncated to 9 Å, is contoured in black. Solid
red contours correspond to the densities above 0 level in the difference map made by subtracting the TPP+–EmrE density
from the apo-EmrE density; the 0 contour is omitted. Dotted blue contours correspond to negative densities in the same
difference map. (c–e) Projection maps of Eth+-, PP2+- and DQ2+-bound EmrE, respectively, and corresponding apo-EmrE
difference maps are contoured as in b. Resolution of each map 9 Å. (f–h) Comparison between the TPP+- and the planar
drug-bound EmrE. Projection maps at 9 Å of Eth+-, PP2+- and DQ2+-bound EmrE, respectively, are contoured in black.
Solid red and dotted blue contours correspond to positive and negative densities in the difference maps between planar
ligand-bound EmrE and TPP+–EmrE maps (as in c–e).
1100 Cryo-EM Determination of EmrE Structuresmultidrug binding proteins, such as BmrR and
QacR,14,15 and from the X-ray structures of the
multidrug transporter of the RND family member,
AcrB20 (several other putative multidrug transporter
structures have been solved, albeit without any
substrates bound18,19). The structures of these pro-
teins revealed large drug binding sites containing
discrete subsites in which different drugs can
bind.14,15,20 In some cases, binding of several drugs
was shown to occur simultaneously, leading to a
‘cross-talk’ between the ligands and their binding
sites.20,21 Importantly, in all cases where multidrug
binding proteins or transporters were co-crystallized
with the drugs, recognition of different drugs by the
same binding site was associated with little, if any,
difference in the conformational state of the protein.13
The drug binding site of EmrE is formed by the
transmembrane domains of the protein. This puts
several evolutionary constraints on the EmrE drug
binding site: (i) there must be at least two orienta-
tions of the substrate binding site (inward- and
outward-facing orientation), with different affinities
for the substrates, allowing substrate translocation
across the bacterial inner membrane; (ii) inherently,
this implies a certain degree of flexibility of theprotein; (iii) specificity for multiple drugs must be
combined with strong coupling to the H+-gradient,
preventing ‘leaky’ passage of ions or small mole-
cules. Maintaining these three conditions would
present a challenge for a small protein like EmrE
with a large pocket containing multiple discrete
binding sites for different classes of drugs.
Here, using cryo-EM we show that, to accommo-
date drugs with planar and tetrahedral geometry,
EmrE undergoes distinct conformational rearrange-
ments. The structural changes are similar for mono-
and bivalent planar drugs (Eth+ and PP2+, respec-
tively). We are able to identify the position of the
bound ligand in all three new projection structures
at 9 Å resolution (confirmed for Eth+–EmrE down to
7 Å resolution), confirming that there are no subsites
for different substrates in the EmrE binding site.
Furthermore, we identify three regions surrounding
the drug binding site, which change in response to
binding of planar drugs (Eth+, PP2+ and DQ2+) in a
way different from the changes upon TPP+ binding.
Remodelled regions of the protein include trans-
membrane helices in area A2 and B3, as well as the
junction between helices at the boundary between
areas 2 and 3. The peak corresponding to movement
Fig. 5. Comparison of the three different conforma-
tional states of EmrE at higher (7 Å) resolution. (a, b) The
projection maps of EmrE bound to either TPP+ or Eth+ and
the differences between these maps and the apo-EmrE are
shown with the same representation as in Fig. 4b and c.
(c) Differences between Eth+ and TPP+-bound EmrE are
shown with the same representation as in Fig. 4f.
Resolution of all the maps is 7 Å.
1101Cryo-EM Determination of EmrE Structuresof the helix in area C1 is broadened in the planar
drug–EmrE projection structures, although its posi-
tion is not greatly changed. This may indicate
intrinsic flexibility of this region of the protein, a
property that may be necessary for drug binding
and translocation across the membrane. The precise
nature of the conformational changes will remainTable 3. Cross-correlation coefficients for the comparison of
Abbreviations used here: A, T, E, P and D stand for apo-EmrE, TPP+
indicates the difference density map calculated by subtracting the
a Cross-correlation coefficients determined using the difference maunresolved until 3D structures at higher resolution
become available.
Our findings indicate that in contrast to other
multidrug binding proteins, rather than having a
large cavity with discrete niches for different
substrates, EmrE has evolved a binding site that is
remodelled dependent on the geometry of the
substrate. Remodelling is achieved by subtle changes
in the structure of the protein, resulting in altered
positions of the transmembrane domains within the
projection structures.Materials and Methods
Protein expression and purification
Expression and purification of EmrE was performed as
described previously.3 Briefly, E. coli membranes contain-
ing 6xHis-tagged EmrE were solubilized with dodecyl-
maltoside (DDM, Glycon, Germany). The protein was
then purified using a 3-step procedure that included
NiNTA-agarose (Qiagen), gel filtration (Superdex 200,
Amersham) and anion exchange (PI, Poros). Purity of the
protein preparations was assessed by SDS-PAGE.
Radioligand binding assays
To quantify the efficiency of ligand exchange at the 2-D
crystals, radioligand binding assays were used. For that
purpose, the 2-D crystals obtainedwithTPP+were subjected
to dialysis against a low pH buffer (pH 5), to remove bound
TPP+. A saturating amount of the resulting 2-D crystals was
mixed with [3H]TPP+ (final concentration 400 nM; Amer-
sham) in the crystallization buffer (Tris pH 7.5, NaCl
100 mM, ethylenediaminetetraacetic acid (EDTA) 1 mM).
Themixwas diluted 1000-foldwith the crystallization buffer
in the absence and in the presence of propidium iodide
(15 μM) or dequalinium (50 μM). After 5 h incubation at
22 °C, 1ml of the dilutedmixwas filtered thoughGF/B filter
(Millipore) and washed with ice-cold buffer. Liquid
scintillant was added and radioactivity bound to the filter
was counted. Non-specific binding was determined by
adding 100 μM cold TPP+ (Sigma). Competition binding
assays were performed as described previously.62-D crystallization
Crystallization of tubular crystals of EmrE in complex
with ethidium bromide was performed essentially asall possible combinations of difference maps
, ethidium, propidium and dequalinium, respectively; thus ‘A-T
density for TPP+-bound EmrE from the density for apo-EmrE.
ps calculated at 7 Å resolution are shown in parentheses.’
1102 Cryo-EM Determination of EmrE Structuresthat for the TPP+-bound form.3 EmrE at concentration
of 0.5–1 mg/ml was mixed with dimyristoylphospha-
tidylcholine (DMPC; Avanti Polar Lipids) at lipid to
protein ratios of 0.3–0.4. Crystallization was performed
in a dialysis cassette (Slide-a-lyzer, 10 kDa cut-off, 0.1–
0.5 ml, Pierce) for a week, with a daily buffer exchange
(pH 7.5) with a buffer containing 1 mM ethidium
bromide.
Ligand exchange
To obtain the crystals of EmrE bound to propidium
iodide and dequalinium, the TPP+-bound EmrE crystals
were employed. A suspension of the TPP+–EmrE crystals
(100 μl, 1 mg/ml protein concentration, 200 nM TPP+) was
dialysed for 5 h at 22 °C against a 1000-fold excess of the
same buffer containing the desired ligand (50 μM propi-
dium or 15 μM dequalinium; Sigma). The concentrations
of propidium and dequalinium were well above the
determined Ki values (2632 times and 181 times,
respectively) for binding to EmrE. A 1000-fold dilution
of the TPP+ in the crystal suspension dilutes it to 10-fold
below its Kd to optimise ligand exchange. In Fig. 1c, this
would mean equilibrium would have been reached if
the amount of 3H-TPP+ left bound was 3.5 dpm,
whereas after exchange the amount left bound when
exchanged for propidium was 105 dpm and 35 dpm in
the presence of unlabelled TPP+ or dequalinium. Longer
incubations were avoided to prevent deterioration of the
crystals.
Electron microscopy
Crystals were deposited onto glow-discharged carbon-
coated electron microscopy grids, blotted, washed with a
solution containing 2% glucose, blotted again, and
plunged into liquid nitrogen. The frozen gridswere loaded
onto a liquid nitrogen-cooled Gatan 626 cryostage and
analysed by low-dose cryo-EM techniques (10–15 e Å−2)
on a Technai F20 electron microscope at an accelerating
voltage of 200 keV. Images were collected with flood
beam illumination at a magnification of 50,000×–58,000×.
The quality of the images was assessed by optical
diffraction. The best images were digitized using the
MRC KZA scanner with a 6 μm step size.22 Image
processing was performed using the MRC package.
Projection structures were built according to previously
described procedures, using MRC software.17 Averaging
of the asymmetric dimers within the crystallographic
tetramer was done using INTERPO, a program for image
interpolation. In brief, the p2 maps were rotated by
approximately 17° (slightly different angles were used for
each map; Table 2), to enable assignment of an
orthogonal (90°) coordinate system to each projection
map. This allowed the direct comparison of maps from
either p2 or c222 crystal forms. An area corresponding
to the EmrE crystallographic tetramer was cut out from
each map using LABEL, and then the same program
was used to create a mirror image of the cut out
image. TWOFILE was then used to calculate difference
maps between the two mirror images. Iterative adjust-
ment of the angle of rotation and the position of the
cut out region was performed until the lowest RMS
deviation of the mirror difference map was reached
(“RMS mirr.”; Table 2). The procedure was repeated
with all projection maps merged at 7, 8, 9 and 10 Å
resolution. TWOFILE was then used to compare the
averaged projection maps at corresponding resolutions;each projection map was scaled to obtain minimal RMS
of the difference map (“RMS diff.”; Table 2). Cross-
correlation of the difference maps was performed with
the mean density values, using the equation: σ=(A·B)/
sqrt(A2·B2), where A and B are mean densities of the two
correlated difference maps; multiplication of images
required for the cross-correlation calculation was done
using TWOFILE.Acknowledgements
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